Silexion regains Nasdaq compliance with $9.4M equity after capital raise

Silexion Therapeutics Corp

Issued 450,000 shares to sponsor upon converting $1.8M of convertible note at $4.00/share; remaining $1.6M outstanding.
Shareholders' equity rose to ~$9.4M from -$0.7M at July 31, 2025, after four transactions.
Company affirms compliance with Nasdaq Capital Market equity requirement of $2.5M and expects long-term compliance.
Gross proceeds from September 2025 public offering: ~$6.0M from sale of shares/pre-funded warrants and warrants.
Warrant exercise inducement in August 2025 generated ~$1.8M gross proceeds.

item 3.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.